Free Trial
→ Do NOT Buy SpaceX Until You See “Mission X” (From StocksToTrade) (Ad)tc pixel
NASDAQ:ALVO

Alvotech Q3 2026 Earnings Results & Report

Alvotech logo
$4.92 +0.04 (+0.82%)
Closing price 11/11/2026 04:00 PM Eastern
Extended Trading
$4.62 -0.31 (-6.20%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alvotech beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 11, 2026. The company reported EPS of -$0.03 versus the -$0.0369 consensus estimate, while revenue of $111.60 million fell short of the $125.20 million estimate by $13.60 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call Date
Conference Call
8:00 AM ET
Upcoming Event
Earnings Conference Call
Alvotech Q3 2026
00:00 / 00:00
Live Transcript
Follow Audio

Alvotech EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.0369
Beat/Miss
Beat by +$0.0069
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Alvotech Revenue Results

Actual Revenue
$111.60 million
Expected Revenue
$125.20 million
Beat/Miss
Missed by -$13.60 million
YoY Revenue Growth
N/A

Conference Call Resources

Slide Deck

Alvotech's Q3 2026 Slide DeckFull Screen Slide Deck
Powered by Quartr

Earnings Documents

Alvotech's Q3 2026 Press ReleasePress Release
(6-K)

Alvotech Q3 2026 Earnings FAQ

Alvotech (NASDAQ:ALVO) reported earnings of -$0.03 per share for Q3 2026, beating the consensus estimate of -$0.0369. The report was announced on Wednesday, November 11, 2026.

Alvotech reported revenue of $111.60 million for Q3 2026, against a consensus estimate of $125.20 million.

Alvotech Earnings Headlines

Jefferies Financial Group Initiates Coverage on Alvotech (NASDAQ:ALVO)
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31193000
Alvotech Q3 Revenue Falls
November 11 at 8:16 PM  |  marketscreener.comM
Executive Order 14241 Unleashes Trump’s New Dollar
A landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.tc pixel
 |  Porter & Company (Ad)
Alvotech Reports Third Quarter and Nine-Month 2026 Financial Results and Business Update
November 11 at 4:31 PM  |  quiverquant.comQ
Alvotech Reports 9M 2026 Financial Results and Provides Business Update
November 11 at 4:31 PM  |  quiverquant.comQ
Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
November 11 at 4:15 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/11/3401138/0/en/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update.html
See More Alvotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alvotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alvotech and other key companies, straight to your email.

About Alvotech

Alvotech (NASDAQ:ALVO) is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology.

Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

View Alvotech Profile
Earnings Tools